CellVec is a certified GMP gene therapy CDMO that specializes in the development and manufacture of custom viral vectors for preclinical and clinical applications. Their cutting-edge CellVec Vector Platform allows them to overcome current technological challenges in viral vector scale-up and to develop novel gene transfer technologies for advanced therapies. Their goal is to advance their clients’ projects from bench to bedside for clinical applications. CellVec was founded in 2018 as a subsidiary of TalkMed Group and currently operates out of Singapore.